Browse TNFRSF10B

Summary
SymbolTNFRSF10B
Nametumor necrosis factor receptor superfamily, member 10b
Aliases DR5; KILLER; TRICK2A; TRAIL-R2; TRICKB; CD262; KILLER/DR5; TRAILR2; TRICK2; TRICK2B; ZTNFR9; Fas-like protei ......
Chromosomal Location8p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF00531 Death domain
PF00020 TNFR/NGFR cysteine-rich region
Function

Receptor for the cytotoxic ligand TNFSF10/TRAIL (PubMed:10549288). The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis.

> Gene Ontology
 
Biological Process GO:0002237 response to molecule of bacterial origin
GO:0006919 activation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007250 activation of NF-kappaB-inducing kinase activity
GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors
GO:0009612 response to mechanical stimulus
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0032147 activation of protein kinase activity
GO:0032496 response to lipopolysaccharide
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0033674 positive regulation of kinase activity
GO:0034612 response to tumor necrosis factor
GO:0034976 response to endoplasmic reticulum stress
GO:0038061 NIK/NF-kappaB signaling
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0045860 positive regulation of protein kinase activity
GO:0045862 positive regulation of proteolysis
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0070059 intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress
GO:0071214 cellular response to abiotic stimulus
GO:0071260 cellular response to mechanical stimulus
GO:0071356 cellular response to tumor necrosis factor
GO:0071496 cellular response to external stimulus
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097193 intrinsic apoptotic signaling pathway
GO:0097296 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
GO:1901222 regulation of NIK/NF-kappaB signaling
GO:1901224 positive regulation of NIK/NF-kappaB signaling
GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2001056 positive regulation of cysteine-type endopeptidase activity
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001235 positive regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
GO:2001267 regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
GO:2001269 positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway
Molecular Function GO:0005031 tumor necrosis factor-activated receptor activity
GO:0005035 death receptor activity
GO:0045569 TRAIL binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04115 p53 signaling pathway
hsa04210 Apoptosis
hsa04650 Natural killer cell mediated cytotoxicity
Reactome R-HSA-109581: Apoptosis
R-HSA-5218900: CASP8 activity is inhibited
R-HSA-5357769: Caspase activation via extrinsic apoptotic signalling pathway
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-73887: Death Receptor Signalling
R-HSA-69416: Dimerization of procaspase-8
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-109582: Hemostasis
R-HSA-140534: Ligand-dependent caspase activation
R-HSA-5357801: Programmed Cell Death
R-HSA-5213460: RIPK1-mediated regulated necrosis
R-HSA-5218859: Regulated Necrosis
R-HSA-3371378: Regulation by c-FLIP
R-HSA-5675482: Regulation of necroptotic cell death
R-HSA-162582: Signal Transduction
R-HSA-5633008: TP53 Regulates Transcription of Cell Death Genes
R-HSA-6803211: TP53 Regulates Transcription of Death Receptors and Ligands
R-HSA-75158: TRAIL signaling
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolTNFRSF10B
Nametumor necrosis factor receptor superfamily, member 10b
Aliases DR5; KILLER; TRICK2A; TRAIL-R2; TRICKB; CD262; KILLER/DR5; TRAILR2; TRICK2; TRICK2B; ZTNFR9; Fas-like protei ......
Chromosomal Location8p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TNFRSF10B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TNFRSF10B and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24639349MelanomaPromote immunity (T cell function); essential for immunotherapyHistone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway. CTL resistance was due to DR5 downregulation and an inverted ratio of pro- to antiapoptotic molecules, both of which were reversed by the histone deacetylase inhibitor suberoylanilide hydroxanic acid.
16680149Breast Carcinoma; Renal Cell Carcinoma; Colon Carcinoma; Lung CarcinomaPromote immunityHere we show that induction of tumor-cell apoptosis by an agonistic monoclonal antibody to DR5, the apoptosis-inducing receptor for TNF-related apoptosis-inducing ligand (TRAIL), combined with T-cell activation by agonistic monoclonal antibodies to the costimulatory molecules CD40 and CD137, potently and rapidly stimulated tumor-specific effector CD8+ T cells capable of eradicating preestablished tumors. This combination therapy of three monoclonal antibodies (trimAb) rapidly induced tumor-specific CD8+ T cells producing interferon (IFN)-gamma in the tumor-draining lymph node, consistent with a crucial requirement for CD8+ T cells and IFN-gamma in the tumor rejection process.
22419388Triple-Negative Breast CarcinomaImmunotherapy targetResulting immune serum or purified immune IgG induced apoptosis in triple-negative breast cancer (TNBC) cells, which were also TRAIL sensitive. Apoptotic cell death induced by anti-DR5 antibody was shown by the cleavage of PARP and caspase-3. In vivo, hDR5 reactive immune serum prevented growth of SUM159 TNBC cells in severe combined immune-deficient mice. These findings support DR5 as a promising vaccine target for controlling TNBC and other DR5-positive cancers.
19147771Renal Cell CarcinomaInhibit immunityThe death ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors (TRAIL-R) are involved in immune surveillance and tumor development. High TRAIL-R2 expression levels were associated with high-grade RCCs (P < 0.001) and correlated negatively with disease-specific survival (P = 0.01). Similarly, high TRAIL expression was associated with a shorter disease-specific survival (P = 0.01).
Summary
SymbolTNFRSF10B
Nametumor necrosis factor receptor superfamily, member 10b
Aliases DR5; KILLER; TRICK2A; TRAIL-R2; TRICKB; CD262; KILLER/DR5; TRAILR2; TRICK2; TRICK2B; ZTNFR9; Fas-like protei ......
Chromosomal Location8p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TNFRSF10B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTNFRSF10B
Nametumor necrosis factor receptor superfamily, member 10b
Aliases DR5; KILLER; TRICK2A; TRAIL-R2; TRICKB; CD262; KILLER/DR5; TRAILR2; TRICK2; TRICK2B; ZTNFR9; Fas-like protei ......
Chromosomal Location8p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TNFRSF10B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3970.472
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.020.993
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6650.661
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2770.469
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.160.941
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4260.879
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2720.652
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4730.8
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1690.931
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.10.95
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7260.76
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.340.00157
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TNFRSF10B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTNFRSF10B
Nametumor necrosis factor receptor superfamily, member 10b
Aliases DR5; KILLER; TRICK2A; TRAIL-R2; TRICKB; CD262; KILLER/DR5; TRAILR2; TRICK2; TRICK2B; ZTNFR9; Fas-like protei ......
Chromosomal Location8p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNFRSF10B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTNFRSF10B
Nametumor necrosis factor receptor superfamily, member 10b
Aliases DR5; KILLER; TRICK2A; TRAIL-R2; TRICKB; CD262; KILLER/DR5; TRAILR2; TRICK2; TRICK2B; ZTNFR9; Fas-like protei ......
Chromosomal Location8p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNFRSF10B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNFRSF10B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTNFRSF10B
Nametumor necrosis factor receptor superfamily, member 10b
Aliases DR5; KILLER; TRICK2A; TRAIL-R2; TRICKB; CD262; KILLER/DR5; TRAILR2; TRICK2; TRICK2B; ZTNFR9; Fas-like protei ......
Chromosomal Location8p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNFRSF10B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTNFRSF10B
Nametumor necrosis factor receptor superfamily, member 10b
Aliases DR5; KILLER; TRICK2A; TRAIL-R2; TRICKB; CD262; KILLER/DR5; TRAILR2; TRICK2; TRICK2B; ZTNFR9; Fas-like protei ......
Chromosomal Location8p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TNFRSF10B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTNFRSF10B
Nametumor necrosis factor receptor superfamily, member 10b
Aliases DR5; KILLER; TRICK2A; TRAIL-R2; TRICKB; CD262; KILLER/DR5; TRAILR2; TRICK2; TRICK2B; ZTNFR9; Fas-like protei ......
Chromosomal Location8p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TNFRSF10B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTNFRSF10B
Nametumor necrosis factor receptor superfamily, member 10b
Aliases DR5; KILLER; TRICK2A; TRAIL-R2; TRICKB; CD262; KILLER/DR5; TRAILR2; TRICK2; TRICK2B; ZTNFR9; Fas-like protei ......
Chromosomal Location8p22-p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TNFRSF10B collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TNFRSF10B.
ID Name Drug Type Targets #Targets
DB05895HGS-TR2JBiotechTNFRSF10B1
DB06599LexatumumabBiotechTNFRSF10B1